The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial

Aim: To assess the impact of the SGLT2 inhibitor empagliflozin (25mg once-daily), dietary energy restriction, or both combined, on circulating appetite-regulatory peptides in people with type 2 diabetes (T2D) and overweight or obesity.  Materials and Methods: In a double-blind, placebo-controlled tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jack Sargeant, James King, Thomas Yates, Emma Redman, Danielle Bodicoat, Sudesna Chatterjee, Charlotte Edwardson, Laura Gray, Benoit Poulin, Ghazala Waheed, Helen Waller, David Webb, Scott Willis, John Wilding, Kamlesh Khunti, David Stensel, Melanie Davies
Format: Default Article
Published: 2022
Subjects:
compensation
energy balance
energy restriction
gut hormones
SGLT2 inhibitors
Online Access:https://hdl.handle.net/2134/19614447.v1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items